Related Experiment Video
Updated: Jun 7, 2026
07:24
Paramagnetic Relaxation Enhancement for Detecting and Characterizing Self-Associations of Intrinsically Disordered Proteins
Published on: September 23, 2021
Targeting the intrinsically disordered AR-NTD through a machine learning-based enhanced sampling workflow
Kai Zhu1,2,3, Huating Wang1,2,3, Jintu Zhang1,2,3
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Nature Communications
|June 5, 2026
Summary
Researchers developed a computational method to design drugs targeting the intrinsically disordered N-terminal domain of the androgen receptor (AR-NTD) in prostate cancer. This approach identified K53, a novel antagonist with potent anti-cancer activity against resistant cells.
Area of Science:
- Biochemistry
- Computational Biology
- Oncology
Background:
- The androgen receptor N-terminal domain (AR-NTD) is a key target for prostate cancer therapy.
- Its intrinsically disordered nature presents challenges for drug development, leading to resistance.
- Developing new strategies to target the AR-NTD is crucial for overcoming treatment resistance.
Purpose of the Study:
- To develop a computational workflow for identifying druggable conformations of the AR-NTD.
- To elucidate the binding mechanism of AR-NTD modulators.
- To discover novel AR-NTD antagonists for resistant prostate cancer.
Main Methods:
- Utilized enhanced sampling techniques and machine learning for computational analysis.
- Characterized metastable states of the AR-NTD Tau-5 region.
- Performed structure-based virtual screening to identify potential drug candidates.
Main Results:
- Identified nine metastable states of the AR-NTD Tau-5 region.
- Revealed ligand recognition driven by π-π stacking and water-mediated hydrogen bonds.
- Discovered K53, a novel AR-NTD antagonist with potent anti-proliferative activity in resistant prostate cancer cells.
Conclusions:
- The study presents a successful computational paradigm for targeting intrinsically disordered proteins.
- K53 demonstrates direct binding to AR-NTD, suppresses transcriptional activity, and shows cancer cell selectivity.
- K53 represents a promising therapeutic candidate for treating resistant prostate cancer.
